medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 2

<< Back

Rev Mex Urol 2024; 84 (2)

A case report of MiNEN: concomitant primary small-cell neuroendocrine carcinoma and high-grade papillary urothelial carcinoma of the urinary badder. Composite or Collision Tumor?

Franco-Buenaventura D, Ortiz-Tenorio DF, Cortés A, García-Perdomo HA

Language: English
References: 18
Page: 1-10
PDF size: 271.66 Kb.


ABSTRACT

Bladder cancer is the tenth most diagnosed cancer worldwide, and urothelial carcinoma is the most common histologic type. On the contrary, small primary cell neuroendocrine carcinoma of the bladder is sporadic and accounts for less than 1% of all bladder tumors. These malignancies can be observed in mixed neuroendocrine/ non-neuroendocrine neoplasms (MiNENs), which have been studied more in the gastrointestinal tract and lungs but scarcely in this organ due to their low incidence. There are concerns about the pathogenic connection between these two tumors, and the limited evidence accounts for the lack of consensus regarding prognosis and treatment for these patients; therefore, they may need a multimodal approach. Here, we describe the case of a 63-year-old woman who presented with gross hematuria, weight loss, and hypogastric discomfort for the past five months. An intravesical mass was found, and transurethral resection was performed. The Histopathology revealed a high-grade papillary urothelial carcinoma with an invasive component through muscularis propria of the bladder, so she was taken to radical cystectomy with extended pelvic lymphadenectomy. The final pathology report revealed an accompanying primary small cell neuroendocrine carcinoma intermingled with the urothelial one. She received postoperative adjuvant chemotherapy and finally died six months after surgery.


REFERENCES

  1. Li Z, Lin C, Wang D, Xie J, Zhou C, Chen P, et al.Primary small‑cell neuroendocrine carcinomaof the urinary bladder: A rare case and a reviewof the literature. Molecular and Clinical Oncology. 2018; https://doi.org/10.3892/mco.2018.1679.

  2. Humphrey PA, Moch H, Cubilla AL, UlbrightTM, Reuter VE. The 2016 WHO Classificationof Tumours of the Urinary System and MaleGenital Organs—Part B: Prostate and BladderTumours. European Urology. 2016;70(1):106–119. https://doi.org/¡ https://doi.org/10.1016/j.eururo.2016.02.028.

  3. Oh J, Eigl B, Black PC, Pickles T, Villamil C,Sunderland K, et al. Small cell carcinoma of thebladder: A population-based analysis of longtermoutcomes after radical cystectomy andbladder conservation with chemoradiotherapy.Canadian Urological Association Journal.2021;16(2). https://doi.org/10.5489/cuaj.7411.

  4. Chraïbi M, Barqui M. Small Cell NeuroendocrineCarcinoma of the Urinary Bladder: Rare EntityAssociated to Poor Prognosis. InternationalArchives of Urology and Complications.2019;5(1). https://doi.org/10.23937/2469-

  5. 5742/1510055.5. Sehgal SS, Wein AJ, Bing Z, Malkowicz SB,Guzzo TJ. Neuroendocrine tumor of the bladder.Reviews in Urology. 2010;12(4): e197-201.

  6. Bhavsar T, Liu J, Huang Y. Collision metastasisof urothelial and prostate carcinomas to thesame lymph node: a case report and review ofthe literature. Journal of Medical Case Reports.2012;6(1): 124. https://doi.org/10.1186/1752-1947-6-124.

  7. Michalinos A, Constantinidou A, Kontos M.Gastric Collision Tumors: An Insight into TheirOrigin and Clinical Significance. GastroenterologyResearch and Practice. 2015;2015: 1–8. https://doi.org/10.1155/2015/314158.

  8. Church DN, Bahl A. Clinical review - small cellcarcinoma of the bladder. Cancer TreatmentReviews. 2006;32(8): 588–593. https://doi.org/10.1016/j.ctrv.2006.07.013.

  9. Lohrisch C, Murray N, Pickles T, Sullivan L.Small cell carcinoma of the bladder: long termoutcome with integrated chemoradiation.Cancer. 1999;86(11): 2346–2352. https://doi. org/10. 1002/(sici) 1097-0142(19991201)86:11<2346::aid-cncr24>3.0.co;2-5.

  10. Choong NWW, Quevedo JF, Kaur JS. Small cellcarcinoma of the urinary bladder: The MayoClinic experience. Cancer. 2005;103(6): 1172–

  11. 1178. https://doi.org/10.1002/cncr.20903.11. Siefker -Radtke Arlene O., Dinney CP,Abrahams NA, Moran C, Shen YU, PistersLL, et al. Evidence supporting preoperativechemotherapy for small cell carcinoma ofthe bladder: a retrospective review of the m.d. anderson cancer experience. Journal ofUrology. 2004;172(2): 481–484. https://doi.org/10.1097/01.ju.0000132413.85866.fc.

  12. Chen Z, Liu Q, Chen R, Liu Z, Li M, Ling Q,et al. Clinical analysis of small cell carcinomaof the bladder in Chinese: nine case reportsand literature reviews. World Journal ofSurgical Oncology. 2017;15(1): 33. https://doi.org/10.1186/s12957-016-1079-y.

  13. Mackey JR, Au HJ, Hugh J, Venner P.Genitourinary small cell carcinoma:determination of clinical and therapeuticfactors associated with survival. Journal ofUrology. 1998;159(5): 1624–1629. https://doi.org/10.1097/00005392-199805000-00058.

  14. Sellman DP, Peard L, Simpson G, Lancaster K,Kavuri S, Terris M, et al. Collision metastasisof prostatic adenocarcinoma and urothelialcarcinoma of the bladder. Urology Annals.2018;10(3): 342–344. https://doi.org/10.4103/ua.ua_97_17.

  15. Howe JR, Merchant NB, Conrad C, KeutgenXM, Hallet J, Drebin JA, et al. The NorthAmerican Neuroendocrine Tumor SocietyConsensus Paper on the Surgical Management ofPancreatic Neuroendocrine Tumors. Pancreas.2020;49(1): 1–33. https://doi.org/10.1097/mpa.0000000000001454.

  16. Zhang P, Duan J, Bai H, Wang Z, Gao S, TanF, et al. Influence of adjuvant chemotherapyon survival for patients with stage IB andIIA non-small cell lung cancer. ThoracicCancer. 2021;12(1): 30–39. https://doi.org/10.1111/1759-7714.13685.

  17. Jiang S, Wang J, Yang C, Tan R, Hou J, Shi Y, etal. Continuous culture of urine-derived bladdercancer cells for precision medicine. Protein& Cell. 2019;10(12): 902–907. https://doi.org/10.1007/s13238-019-0649-5.

  18. Akazawa Y, Higashiyama M, Nishino K,Uchida J, Kumagai T, Inoue T, et al. Impact ofin vitro chemosensitivity test-guided platinumbasedadjuvant chemotherapy on the surgicaloutcomes of patients with p-stage IIIA nonsmallcell lung cancer that underwent completeresection. Molecular and Clinical Oncology.2017;7(3): 327–335. https://doi.org/10.3892/mco.2017.1340.




2020     |     www.medigraphic.com